{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"18.8","value":"10.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Time from tumor response date to disease progression or death for any reason.","dispersionType":"Full Range","groups":[{"description":"Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.\n\nAvelumab: Avelumab through a vein once every 2 weeks","id":"OG000","title":"Avelumab Monotherapy"}],"paramType":"MEDIAN","populationDescription":"Patients who had partial response.","reportingStatus":"POSTED","timeFrame":"Date of first partial or complete response as defined by RECIST 1.1 criteria to date of recurrence or disease progression up to 3 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}